Please login to the form below

Not currently logged in
Email:
Password:

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

teva phillip frost Teva's chairman Phillip Frost will resign his position by the end of 2014.

According to Reuters Frost (pictured right) wrote to shareholders in a letter: "With the progress we have made, and continue to make, at Teva, I have advised the board that I believe it will be appropriate for me to step down as chairman approximately by the end of this year.”

The announcement comes just three weeks after Israel-based Teva announced a restructure of its business to give stronger identify to its branded and generics divisions, including several new senior appointments.

The past few months has been a time of transition for Teva; the company also saw a change in CEO with the appointment of Erez Vigodman to replace Jeremy Levin, who, according to local news reports, had a strained relationship with Frost.

And at the beginning of 2014, the company announced that board director Amir Elstein to replace Prof Moshe Many as vice chairman.

20th June 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics